|
Onapristone (ONA) in progesterone receptor (PR)-expressing tumors: Efficacy and biomarker results of a dose-escalation phase 1 study. |
|
|
Research Funding - Arno Therapeutics (Inst) |
|
|
Research Funding - Arno Therapeutics (Inst) |
|
|
Research Funding - Arno Therapeutics (Inst) |
|
|
Research Funding - Arno Therapeutics (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - MSD Oncology; Roche |
Travel, Accommodations, Expenses - AstraZeneca; PharmaMar; Roche; Vifor Pharma |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Arno Therapeutics |
|
|
Consulting or Advisory Role - Arno Therapeutics |
Patents, Royalties, Other Intellectual Property - Arno Therapeutics |
|
|
Employment - Arno Therapeutics |
Leadership - Arno Therapeutics |
Stock and Other Ownership Interests - Arno Therapeutics |
|
|
Employment - Arno Therapeutics |
Leadership - Arno Therapeutics |
Stock and Other Ownership Interests - Arno Therapeutics |
|
|
Employment - Arno Therapeutics |
Leadership - Arno Therapeutics |
Stock and Other Ownership Interests - Arno Therapeutics |
Patents, Royalties, Other Intellectual Property - Arno Therapeutics |
|
|
Consulting or Advisory Role - Invivis |
|
|
Research Funding - Arno Therapeutics (Inst) |